Overview

Detailed Summary

Ortin Laboratories Limited is a leading pharmaceutical manufacturer in India, specializing in a wide range of pharma formulations including tablets, capsules, syrups, and ointments.
The company has strategically expanded its manufacturing capabilities and geographical reach by obtaining certifications for exports to Asian, African, and Middle East countries.
Ortin Laboratories expanded its business scope through the amalgamation with Vineet Laboratories, enhancing its portfolio with fine chemicals and bulk drug intermediates.
The company's manufacturing facilities adhere to WHO GMP Standards, marking a commitment to quality and international compliance.
Ortin Laboratories has consistently upgraded and expanded its facilities, indicating a focus on scaling production and meeting global standards.

Sector: Pharmaceuticals & Biotechnology
Industry: Pharmaceuticals
Market Cap: 12 Cr
Volatility: Low Risk
P/E Ratio: -13.5
Industry P/E: 33.1
PEG Ratio: —
P/B Ratio: 9.5
52W High: 19.15
52W Low: 10.15

Sales CAGR

1Y: -83.89%
3Y: -65.36%
5Y: -71.96%
10Y: -44.38%

Profit CAGR

1Y: 89.43%
3Y: —
5Y: —
10Y: —

ROE

TTM: -73.01%
3Y: -57.33%
5Y: -22.21%
10Y: -3.62%

ROCE

TTM: -42.20%
3Y: -33.90%
5Y: -12.32%
10Y: 7.51%

Technicals

‌

Forecasts

Peers

Healthcare Healthcare Pharmaceuticals

Symbol	Watchlist	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
SAROJA		29.40	13 Cr	11.44	0.85	0.00	7.81	11.27	3.44
DESHRAK		24.55	13 Cr	22.23	1.02	0.00	5.08	7.80	3.24
ORTINGLOBE		15.00	12 Cr	-13.51	9.52	0.00	-73.01	-42.20	-23.24
BERLDRG		21.50	12 Cr	716.67	1.23	0.00	2.47	7.06	0.06
PARMAX		31.18	12 Cr	-2.30	0.00	0.00	75.76	-46.38	-28.70
UNJHAFOR		20.24	9 Cr	8.61	2.16	0.00	23.59	26.37	16.12
DECIPHER		7.50	8 Cr	-0.94	0.43	0.00	-42.34	-50.18	-33.92
Median: 7 Co.	—	21.50	12 Cr	8.61	1.02	0.00	5.08	7.06	0.06

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2011	Mar 2012	Jun 2012
Sales	20	20	16
Expenses	17	21	14
Operating Profit	2.68	-1.00	2.08
OPM %	13.53	-5.06	13.06
Other Income	0.01	0.19	0.03
Interest	0.55	0.98	1.12
Depreciation	0.34	0.39	0.33
Profit Before Tax	1.80	-2.18	0.66
Tax %	33.33	11.93	33.33
Net Profit	1.20	-1.92	0.44
EPS in Rs	—	—	—

Standalone Profit Loss (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	67	81	168	197	8.17	8.23	6.02	2.11	0.34	0.25
Expenses	56	74	161	192	6.92	7.86	5.50	8.65	1.23	1.17
Operating Profit	10	6.31	6.68	5.69	1.25	0.38	0.52	-6.54	-0.88	-0.92
OPM %	15.44	7.83	3.98	2.88	15.25	4.56	8.65	-309.60	-258.21	-368.00
Other Income	0.32	0.45	0.13	0.19	0.05	0.19	0.02	0.17	0.06	NaN
Interest	2.93	3.49	3.22	3.21	0.87	0.81	0.40	0.48	0.00	0.01
Depreciation	1.70	1.69	1.75	1.96	0.29	0.29	0.25	0.23	0.01	0.00
Profit Before Tax	1.13	0.68	1.84	0.72	0.14	-0.53	-0.11	-7.08	-0.84	-0.89
Tax %	55.49	0.18	30.36	178.48	-592.89	24.76	15.29	-13.65	-1.06	-3.37
Net Profit	0.50	0.68	1.28	-0.56	0.95	-0.40	-0.09	-8.04	-0.85	-0.92
EPS in Rs	0.62	0.98	1.56	-0.71	4.53	-0.49	0.36	-9.89	-1.04	-1.11
Dividend Payout %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—

Standalone Balance Sheet (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	17	17	17	17	17	8.13	8.13	8.13	8.13	8.13
Reserves	6.33	6.46	7.14	8.15	6.88	3.22	2.83	2.73	-5.31	-6.15
Borrowings	20	17	16	19	20	6.94	6.14	6.45	1.80	0.25
Other Liabilities	22	22	33	61	73	2.97	3.60	3.89	2.04	1.55
Total Liabilities	65	62	74	105	117	21	21	21	6.66	3.78
Fixed Assets	22	21	20	21	22	14	14	14	0.01	0.00
CWIP	0.00	0.35	0.40	0.53	0.43	0.43	0.43	0.43	0.00	0.00
Investments	0.03	0.07	0.08	0.08	0.07	0.00	0.00	0.00	0.00	0.00
Other Assets	44	40	53	83	94	6.46	6.07	6.81	6.65	3.78
Total Assets	65	62	74	105	117	21	21	21	6.66	3.78

Standalone Cash Flows (in ₹ Crores)

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	0.52	1.94	1.56	6.52	3.30	18	2.15	-0.25	-4.79	-0.41
Cash from Investing Activity	-0.86	-1.26	-0.90	-3.27	-3.09	0.07	-0.13	0.01	12	-0.00
Cash from Financing Activity	0.27	-0.82	0.07	-2.89	-1.33	-9.86	-0.47	0.90	-3.49	0.33
Net Cash Flow	-0.07	-0.14	0.73	0.37	-1.12	8.25	1.55	0.66	3.72	-0.09

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Promoters	7.36%	7.37%	7.36%	1.23%	1.23%	1.23%	1.23%	1.23%	1.23%	1.23%	1.23%	1.23%
FIIs	0.00%	0.00%	0.00%	0.00%	6.25%	6.25%	6.25%	6.53%	6.53%	1.68%	1.68%	1.68%
DIIs	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Public	92.64%	92.63%	92.64%	98.77%	92.52%	92.52%	92.52%	92.24%	92.24%	97.09%	97.09%	97.09%
Total Shareholders	12,181	11,836	12,314	12,192	11,952	12,165	12,094	12,144	12,034	12,060	11,834	11,452

Market Transactions

Unlock more with professional

Real-time bulk & block deal transactions
Export transaction data for analysis

Projection

Documents

Presentations

Concalls

Reports

Presentations

No documents found!

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Sorry, no results found!

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

Ask AI

Frequently Asked Questions about Ortin Global Ltd

Ortin Global Ltd (ORTINGLOBE) is currently trading at 14.50 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Ortin Laboratories Limited is a leading pharmaceutical manufacturer in India, specializing in a wide range of pharma formulations including tablets, capsules, syrups, and ointments. The company has strategically expanded its manufacturing capabilities and geographical reach by obtaining certifications for exports to Asian, African, and Middle East countries. Ortin Laboratories expanded its business scope through the amalgamation with Vineet Laboratories, enhancing its portfolio with fine chemicals and bulk drug intermediates. The company's manufacturing facilities adhere to WHO GMP Standards, marking a commitment to quality and international compliance. Ortin Laboratories has consistently upgraded and expanded its facilities, indicating a focus on scaling production and meeting global standards.

Over the past 52 weeks, Ortin Global Ltd has traded between a low of ₹10.15 and a high of ₹19.15. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Ortin Global Ltd has a market capitalization of approximately 12.38. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Ortin Global Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -13.51 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 12.38 Cr, Ortin Global Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Ortin Global Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Ortin Global Ltd is -13.51. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Ortin Global Ltd

Stock Summary and Key Metrics

Investment Checklist

Investment Checklist

Overview

Financial Ratios

Technicals

Forecasts

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

Ask AI

Consolidated Quarterly Results (in ₹ Crores)

Standalone Profit Loss (in ₹ Crores)

Standalone Balance Sheet (in ₹ Crores)

Standalone Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Unlock more with professional

Projection

Documents

Actions

Announcements

AI Mode

Ask AI

Frequently Asked Questions about Ortin Global Ltd

What is Ortin Global Ltd share price today?

What does Ortin Global Ltd do?

What is the 52-week high and low of Ortin Global Ltd?

What is the market capitalization of Ortin Global Ltd?

Should I consider investing in Ortin Global Ltd stock?

Is Ortin Global Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Ortin Global Ltd belong to and why does it matter?

What is the PE ratio of Ortin Global Ltd?

Investor’s Suite

Market Explorer

Market Pulse

Deep Dive

Utility

Company

Technicals

Forecasts

Projection

Announcements

Frequently Asked Questions about Ortin Global Ltd

What is Ortin Global Ltd share price today?

What does Ortin Global Ltd do?

What is the 52-week high and low of Ortin Global Ltd?

What is the market capitalization of Ortin Global Ltd?

Should I consider investing in Ortin Global Ltd stock?

Is Ortin Global Ltd a large-cap, mid-cap, or small-cap stock?

Which sector does Ortin Global Ltd belong to and why does it matter?

What is the PE ratio of Ortin Global Ltd?

Peers

Price Chart Comparison

Oscillators

Neutral

Overall

Bearish

Moving Averages

Bearish

Overall

Bearish

Overview

Financial Ratios

Investment Checklist